Biogen Inc. (BIIB)

Acerca de Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Al 3 de noviembre de 2026, la acción de Biogen Inc. (BIIB) subió a $252.12, un alza de 1.25% (+$3.11) frente al cierre anterior. En la sesión, las acciones han operado entre $246.25 y $252.43. Eso ubica a BIIB cerca del máximo de su rango de 52 semanas, de $148.51 a $258.78. Biogen Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $36.81 mil millones, con cerca de 270.9 mil acciones negociadas.

Últimas noticias de BIIB

• Should You Buy The Dip In Alnylam Stock?trefis.com· 2 nov, 9:39 a.m. ET
• What Just Happened To Alnylam Stock?trefis.com· 30 oct, 12:51 p.m. ET
• Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysYahoo Finance· 29 oct, 11:58 a.m. ET
• Alphabet downgraded, eBay upgraded: Wall Street's top analyst callsYahoo Finance· 29 oct, 9:47 a.m. ET
• Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Yahoo Finance· 29 oct, 6:59 a.m. ET
• What to expect from Regeneron’s (REGN) Q3 earningsYahoo Finance· 29 oct, 6:11 a.m. ETREGN
• Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash FlowYahoo Finance· 29 oct, 1:18 a.m. ET
• Biogen Q3 Earnings Call Highlightsmarketbeat.com· 28 oct, 6:04 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de BIIB en un solo lugar? Crea una cuenta gratis →

• $AMGN So now, sitting at a mere 10M Market Cap, Seastar (ICU) will generate more revenue than that in 2027 with today's removal of the registry requirement. 7 BDDs, with the most recent for Sepsis as a standalone indication. TAM easily in the billions once adult use approv…

  @SparkyReturns· 3 nov, 10:58 a.m. ET· Alcista

• Everything you need to know about the $18.9M Biogen ($BIIB) Settlement Payout Q: What happened? A: Biogen allegedly misled investors about the commercial launch of Aduhelm, its Alzheimer’s treatment, by overstating payer support and suggesting that Medicare coverage was automa…

  @11thestate· 2 nov, 8:29 a.m. ET

• $PMN $PMN When $LLY and $BIIB works with IgG1 and ProMIS hat the same isotype target but 0 ARIA why would someone compare $ABOS versus Promis ? Soon after unblinding it will show ProMIS is the best AD in class!

  @GoforProMIS· 2 nov, 7:21 a.m. ET· Alcista

• $BIIB Excellent article that nails exactly where BIIB stands right now. So if you want to update your BIIB knowledge or get acquainted with BIIB, this is a must read. https://everyticker.com/quote/BIIB/analysis/biogen-s-immunology-inflection-why-the-apellis-acquisition-marks-t…

  @NVDAMillionaire· 2 nov, 2:23 a.m. ET

• $BIIB is still paying for Apellis in its cost of sales, and the filing puts a number on it. The inventory fair value step-up from the deal ran 100.0 million dollars through cost of sales in the third quarter alone, and 169.7 million dollars over nine months. Total step-up was …

  @KryptonResearch14· 1 nov, 1:31 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →